The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The
https://
ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
the contents by NLM or the National Institutes of Health.
Learn more about our disclaimer.
Haematologica.
2019 Sep; 104(9): 1702–1709.
Hemophilia A and B: molecular and clinical similarities and differences
1
and
2
Giancarlo Castaman
1
Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy
Davide Matino
1
Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy
2.
Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A.
Definitions in hemophilia: communication from the SSC of the ISTH
.
J Thromb Haemost
. 2014;
12
(
11
):1935–1939. [
PubMed
]
[
Google Scholar
]
3.
Santagostino E, Mancuso ME, Tripodi A, et al.
Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile
.
J Thromb Haemost
. 2010;
8
(
4
):737–743. [
PubMed
]
[
Google Scholar
]
4.
Mannucci PM, Franchini M.
Is haemophilia B less severe than haemophilia A?
Haemophilia
. 2013;
19
(
4
):499–502. [
PubMed
]
[
Google Scholar
]
5.
Gitschier J, Wood WI, Goralka TM, et al.
Characterization of the human factor VIII gene
.
Nature
. 1984;
312
(
5992
):326–330. [
PubMed
]
[
Google Scholar
]
6.
Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K.
Complete nucleotide sequences of the gene for human factor IX (antihemophilic factor B)
.
Biochemistry
. 1985;
24
(
14
):3736–3750. [
PubMed
]
[
Google Scholar
]
7.
Belvini D, Salviato R, Radossi P, et al.
Molecular genotyping of the Italian cohort of patients with hemophilia B
.
Haematologica
. 2005;
90
(
5
):635–642. [
PubMed
]
[
Google Scholar
]
8.
Amano K, Sarkar R, Pemberton S, Kemball-Cook G, Kazazian HH, Kaufman RJ.
The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII
.
Blood
. 1998;
91
(
2
):538–548. [
PubMed
]
[
Google Scholar
]
9.
Castaman G, Fijnvandraat K.
Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A
.
Blood
. 2014;
124
(
15
):2333–2336.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
10.
Pinotti M, Caruso P, Canella A, et al.
Ribosome readthrough accounts for secreted full-length factor IX in hemophilia B patients with nonsense mutations
.
Hum Mutat
. 2012;
33
(
9
):1373–1376. [
PubMed
]
[
Google Scholar
]
12.
Kurachi S, Huo JS, Ameri A, Zhang K, Yoshizawa AC, Kurachi K.
An age-related homeostasis mechanism is essential for spontaneous amelioration of hemophilia B Leyden
.
Proc Natl Acad Sci U S A
. 2009;
106
(
19
):7921–7926.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
13.
Funnell APW, Crossley M.
Hemophilia B Leyden and once mysterious cis-regulatory mutations
.
Trends Genet
. 2014;
30
(
1
):18–23. [
PubMed
]
[
Google Scholar
]
14.
Nagel K, Walker I, Decker K, Chan AKC, Pai MK.
Comparing bleed frequency and factor concentrate use between haemophilia A and B patients
.
Haemophilia
. 2011;
17
(
6
):872–874. [
PubMed
]
[
Google Scholar
]
15.
Schulman S, Eelde A, Holmström M, Ståhlberg G, Odeberg J, Blombäck M.
Validation of a composite score for clinical severity of hemophilia
.
J Thromb Haemost
. 2008;
6
(
7
):1113–1121. [
PubMed
]
[
Google Scholar
]
16.
Soucie JM, Monahan PE, Kulkarni R, Konkle BA, Mazepa MA, US Hemophilia Treatment Center Network
The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B
.
Blood Adv
. 2018;
2
(
16
):2136–2144.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
17.
Tagariello G, Iorio A, Santagostino E, et al.
Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders
.
Blood
. 2009;
114
(
4
):779–784. [
PubMed
]
[
Google Scholar
]
18.
Quick AJ, Hussey CV.
Hemophilia B (PTC Deficiency, or Christmas Disease)
.
Arch Intern Med
. 1959;
103
(
5
):762. [
PubMed
]
[
Google Scholar
]
19.
Ludlam CA, Lee RJ, Prescott RJ, et al.
Haemophilia care in central Scotland 1980-94. I. Demographic characteristics, hospital admissions and causes of death
.
Haemophilia
. 2000;
6
(
5
):494–503. [
PubMed
]
[
Google Scholar
]
20.
Soucie JM, Cianfrini C, Janco RL, et al.
Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors
.
Blood
. 2004;
103
(
7
):2467–2473. [
PubMed
]
[
Google Scholar
]
21.
Biss TT, Chan AK, Blanchette VS, Iwenofu LN, Mclimont M, Carcao MD.
The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey
.
Haemophilia
. 2008;
14
(
5
):923–930. [
PubMed
]
[
Google Scholar
]
22.
Tagliaferri A, Di Perna C, Franchini M, Rivolta GF, Pattacini C.
Hemophilia severity score system: validation from an Italian Regional Hemophilia Reference Center
.
J Thromb Haemost
. 2009;
7
(
4
):720–722. [
PubMed
]
[
Google Scholar
]
23.
Clausen N, Petrini P, Claeyssens-Donadel S, Gouw SC, Liesner R.
Similar bleeding phenotype in young children with haemophilia A or B: a cohort study
.
Haemophilia
. 2014;
20
(
6
):747–755. [
PubMed
]
[
Google Scholar
]
24.
Powell JS, Pasi KJ, Ragni MV, et al.
B-LONG investigators. Phase 3 study of recombinant factor IX FGc fusion protein in hemophilia B
.
N Engl J Med
. 2013;
369
(
24
):2313–2323 [
PubMed
]
[
Google Scholar
]
25.
Mahlangu J, Powell JS, Ragni MV, et al.
ALONG Investigators. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
.
Blood
. 2014;
123
(
3
):317–325.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
26.
Melchiorre D, Linari S, Manetti M, et al.
Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A
.
Haematologica
. 2016;
101
(
2
):219–225.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
27.
Mancuso ME, Bidlingmaier C, Mahlangu JN, Carcao M, Tosetto A.
The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH
.
J Thromb Haemost
. 2018;
16
(
10
):2106–2110. [
PubMed
]
[
Google Scholar
]
28.
Linari S, Nichele I, Pieri L, Tosetto A, Castaman G.
Bleeding tendency and clinical phenotype of mild haemophilia A and B
.
Blood Transfusion
. 2018;
16
(
Suppl 4
):s490.
[
Google Scholar
]
29.
den Uijl IEM, Roosendaal G, Fischer K.
Insufficient evidence to suggest less stringent therapy in hemophilia B?
Blood
. 2009;
114
(
23
):4907; author reply 4907-8. [
PubMed
]
[
Google Scholar
]
30.
Arbini A, Mannucci P, Bauer K.
Low Prevalence of the Factor V Leiden Mutation Among “Severe” Hemophiliacs with a “Milder” Bleeding Diathesis
.
Thromb Haemost
. 1995;
74
(
05
):1255–1258. [
PubMed
]
[
Google Scholar
]
31.
Lee DH, Walker IR, Teitel J, et al.
Effect of the Factor V Leiden Mutation on the Clinical Expression of Severe Hemophilia A
.
Thromb Haemost
. 2000;
83
(
03
):387–391. [
PubMed
]
[
Google Scholar
]
32.
Shetty S, Vora S, Kulkarni B, et al.
Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients
.
Br J Haematol
. 2007;
138
(
4
):541–544. [
PubMed
]
[
Google Scholar
]
33.
Van Dijk K, Van Der Bom JG, Fischer K, De Groot PG, Van Den Berg HM.
Phenotype of severe hemophilia A and plasma levels of risk factors for thrombosis
.
J Thromb Haemost
. 2007;
5
(
5
):1062–1064. [
PubMed
]
[
Google Scholar
]
34.
Escuriola Ettingshausen C, Halimeh S, Kurnik K, et al.
Symptomatic Onset of Severe Hemophilia A in Childhood is Dependent on the Presence of Prothrombotic Risk Factors
.
Thromb Haemost
. 2001;
85
(
02
):200–208. [
PubMed
]
[
Google Scholar
]
35.
Tizzano EF, Soria JM, Coll I, et al.
The prothrombin 20210A allele influences clinical manifestations of hemophilia A in patients with intron 22 inversion and without inhibitors
.
Haematologica
. 2002;
87
(
3
):279–285. [
PubMed
]
[
Google Scholar
]
36.
Iorio A, Fischer K, Blanchette V, et al.
Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates
.
Thromb Haemost
. 2017;
117
(
06
):1023–1030. [
PubMed
]
[
Google Scholar
]
38.
Stern DM, Nawroth PP, Kisiel W, V G, E CT.
The binding of factor IXa to cultured bovine aortic endothelial cells. Induction of a specific site in the presence of factors VIII and X
.
J Biol Chem
. 1985;
260
(
11
),6717–6722. [
PubMed
]
[
Google Scholar
]
39.
Cheung WF, van den Born J, Kühn K, Kjellén L, Hudson BG, Stafford DW.
Identification of the endothelial cell binding site for factor IX
.
Proc Natl Acad Sci U S A
. 1996;
93
(
20
):11068–11073.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
40.
Gui T, Reheman A, Ni H, et al.
Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV
.
J Thromb Haemost
. 2009;
7
(
11
):1843–1851. [
PubMed
]
[
Google Scholar
]
41.
Matino D, Iorio A, Stafford D, C A.
Enhanced FIX collagen IV binding shows improved hemostatic effects in a hemophilia B mouse model
.
Res Pract Thromb Haemost
. 2017;
1
:1–1451.
[
Google Scholar
]
42.
Cooley B, Funkhouser W, Monroe D, et al.
Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice
.
Blood
. 2016;
128
(
2
):286–292.
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
43.
Gui T, Lin H-F, Jin D-Y, et al.
Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo
.
Blood
. 2002;
100
(
1
):153–158. [
PubMed
]
[
Google Scholar
]
44.
Bolton-Maggs PHB, Pasi KJ.
Haemophilias A and B
.
Lancet
. 2003;
361
(
9371
):1801–1809. [
PubMed
]
[
Google Scholar
]
45.
Dimichele DM.
Inhibitor treatment in haemophilias A and B: inhibitor diagnosis
.
Haemophilia
. 2006;
12
Suppl 6
:37–42. [
PubMed
]
[
Google Scholar
]
46.
Hay CRM, DiMichele DM, International Immune Tolerance Study
The principal results of the International Immune Tolerance Study: a randomized dose comparison
.
Blood
. 2012;
119
(
6
):1335–1344. [
PubMed
]
[
Google Scholar
]
47.
Dimichele D.
The North American Immune Tolerance registry: contributions to the thirty-year experience with immune tolerance therapy
.
Haemophilia
. 2009;
15
(
1
):320–328 [
PubMed
]
[
Google Scholar
]
48.
Lee CA, Kessler CM, Varon D, Martinowitz U, Heim M, Warrier I.
Management of haemophilia B patients with inhibitors and anaphylaxis
.
Haemophilia
. 1998;
4
(
4
):574–576. [
PubMed
]
[
Google Scholar
]
49.
Tengborn L, Hansson S, Fasth A, Lübeck PO, Berg A, Ljung R.
Anaphylactoid reactions and nephrotic syndrome–a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report on the outcome in two brothers
.
Haemophilia
. 1998;
4
(
6
):854–859. [
PubMed
]
[
Google Scholar
]
50.
Alexander S, Hopewell S, Hunter S, Chouksey A.
Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis
.
J Pediatr Hematol Oncol
. 2008;
30
(
1
):93–95. [
PubMed
]
[
Google Scholar
]
51.
Gill JC, Roberts J, Li Y, Castaman G.
Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B
.
Haemophilia
. 2019.
March
[Epub ahead of print]
[
PMC free article
]
[
PubMed
]
[
Google Scholar
]
52.
Gouw SC, van den Berg HM, Oldenburg J, et al.
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
.
Blood
. 2012;
119
:2922–2934. [
PubMed
]
[
Google Scholar
]
53.
Brummel-Ziedins KE, Mann KG.
Overview of hemostasis
. In Lee CA, Berntorp EE, Hoots WK.
Textbook of haemophilia
, 3rd edition, pages 1–8, Wiley-Blacwell, London, UK, 2014.
[
Google Scholar
]
Articles from
Haematologica
are provided here courtesy of
Ferrata Storti Foundation